Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of HBM9036 (HL036) ophthalmic solution in moderate to severe dry eye
ChiCTR2000039903Phase 3Recruiting
- Sponsor
- Xiamen Eye Center of Xiamen University
- Start
- Dec 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dry eye syndrome (DED) comparing HBM9036 (HL036) eye drops with Placebo eye drops (2 arms). Primary endpoint: Change from baseline in total corneal staining score. Started Dec 2020; status: recruiting.
02
Drugs
tanfanercept
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on ChiCTR2000039903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039903.